Does BOSUTINIB Cause Second primary malignancy? 95 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 95 reports of Second primary malignancy have been filed in association with BOSUTINIB (BOSULIF). This represents 1.2% of all adverse event reports for BOSUTINIB.
95
Reports of Second primary malignancy with BOSUTINIB
1.2%
of all BOSUTINIB reports
13
Deaths
16
Hospitalizations
How Dangerous Is Second primary malignancy From BOSUTINIB?
Of the 95 reports, 13 (13.7%) resulted in death, 16 (16.8%) required hospitalization, and 4 (4.2%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BOSUTINIB. However, 95 reports have been filed with the FAERS database.
What Other Side Effects Does BOSUTINIB Cause?
Diarrhoea (1,820)
Nausea (886)
Fatigue (626)
Vomiting (469)
Death (465)
Rash (426)
Pleural effusion (398)
Neoplasm progression (376)
Dyspnoea (319)
Headache (283)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which BOSUTINIB Alternatives Have Lower Second primary malignancy Risk?
BOSUTINIB vs BOTOX
BOSUTINIB vs BOTOX COSMETIC
BOSUTINIB vs BOTULINUM TOXIN NOS
BOSUTINIB vs BOTULINUM TOXIN TYPE A
BOSUTINIB vs BREMELANOTIDE